Didsbury, United Kingdom

Piers Collier

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Cyclacel Limited. Active years: 2007.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Piers Collier. Retrieved from https://idiyas.com/inventor/piers-collier

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile



Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2007

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Piers Collier: Innovator in Medicinal Chemistry

Introduction

Piers Collier is a notable inventor based in Didsbury, GB. He has made significant contributions to the field of medicinal chemistry, particularly through his innovative patent.

Latest Patents

Piers Collier holds a patent for a medicament, specifically 3β,28-diacetoxy-18-oxo-19,20,21,29,30-pentanorlupan-22-oic acid methanol solvate. This invention relates to its use in medicine and the processes for its preparation. He has 1 patent to his name.

Career Highlights

Throughout his career, Piers has worked with various organizations, including Cyclacel Limited and Charles University in Prague. His work has contributed to advancements in medicinal applications and pharmaceutical research.

Collaborations

Piers has collaborated with notable individuals in his field, including Peter Martin Fischer and Jan Sarek. These partnerships have further enhanced his contributions to medicinal chemistry.

Conclusion

Piers Collier's innovative work in medicinal chemistry and his patent for a unique medicament highlight his role as a significant inventor in the field. His collaborations and career achievements reflect his dedication to advancing medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…